NASDAQ:
TLSA
About
Company Background
Corporate Strategy
Our Team
Focus
Secondary Progressive Multiple Sclerosis
Crohn’s Disease
Type 1 Diabetes
Pulmonary Fibrosis
KRAS+ NSCLC
Platform
Pipeline
Foralumab (TZLS-401)
Anti IL-6R mAb (TZLS-501)
Milciclib (TZLS-201)
Investors
Stock Information
Presentations
Press Releases
Financial Information
Investor Calendar
Governance
Shareholder Services
News
Careers
Contact
Drug Pipeline
Foralumab (TZLS-401)
Anti IL-6R mAb (TZLS-501)
Milciclib (TZLS-201)
Pipeline
Overview
Clinical Trials
